Moderna posts surprise profit
With Trump victorious, biotech industry’s focus turns to his plans for FDA, FTC
Gilead's CAR-T sales stagnate as Trodelvy takes another impairment hit
Sarepta pulls plug on Duchenne exon-skipping drug
*please scroll down for all the latest news*
